Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: A meta-analysis

International Journal of Infectious Diseases

Volumn 16, Issue 11, 2012, Pages

  Vardakas, Konstantinos Z ^a,b   Konstantelias, Athanasios A ^a,c   Loizidis, Giorgos ^a,d   Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,b,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BI NAP1 027; Clostridium difficile; Infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIBLIOGRAPHIC DATABASE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IC 50; MEDLINE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREND STUDY;

AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; RISK FACTORS;

EID: 84868210903     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.07.010     Document Type: Review

References (18)

1. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339.
2. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145:758-764.
3. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
4. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
5. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
6. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
7. Deshpande A., Pant C., Pasupuleti V., Rolston D.D., Jain A., Deshpande N., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:225-233.
8. Barbut F., Mastrantonio P., Delmee M., Brazier J., Kuijper E., Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007, 13:1048-1057.
9. Debast S.B., Vaessen N., Choudry A., Wiegers-Ligtvoet E.A., van den Berg R.J., Kuijper E.J. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009, 15:427-434.
10. Fenner L., Frei R., Gregory M., Dangel M., Stranden A., Widmer A.F. Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007. Eur J Clin Microbiol Infect Dis 2008, 27:1201-1207.
11. Goorhuis A., Debast S.B., Dutilh J.C., van Kinschot C.M., Harmanus C., Cannegieter S.C., et al. Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis 2011, 53:860-869.
12. Goorhuis A., Van der Kooi T., Vaessen N., Dekker F.W., Van den Berg R., Harmanus C., et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in the Netherlands. Clin Infect Dis 2007, 45:695-703.
13. Labbe A.C., Poirier L., Maccannell D., Louie T., Savoie M., Beliveau C., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008, 52:3180-3187.
14. Sundram F., Guyot A., Carboo I., Green S., Lilaonitkul M., Scourfield A. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 2009, 72:111-118.
15. Borriello S.P., Barclay F.E. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 1986, 21:299-309.
16. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
17. Adams D.A., Riggs M.M., Donskey C.J. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007, 51:2674-2678.
18. Kazakova S.V., Ware K., Baughman B., Bilukha O., Paradis A., Sears S., et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006, 166:2518-2524.